Meiji (2269) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
25 Mar, 2026Impairment loss and China business restructuring
Recorded a total impairment loss of JPY 19.4 billion on non-current assets in China, mainly in dairy, B2B, chocolate, and ice cream segments due to underperformance and increased costs.
Despite cost reforms and leveraging brand strength, net sales and profitability fell short, impacted by local competition and post-COVID-19 consumer trends.
Production at the Shanghai ice cream plant was suspended, contributing to cost reductions and a projected reduction in operating losses to JPY 0.8 billion by FY2026.
Profitability improvement efforts included cost reforms, sales area reviews, and focus on high-margin products, especially in B2B and dairy.
Future strategy emphasizes expanding B2B, focusing on differentiated products, and optimizing production and sales strategies in China.
Financial forecast revisions and management policy
FY2025 net sales and operating profit forecasts remain unchanged, but ordinary profit is revised upward due to improved equity method results and FX gains.
Profit attributable to owners is revised downward, reflecting impairment losses and restructuring costs.
Structural reforms and strategic cash allocation are prioritized to restore growth and target an ROE of 10%.
Commitment to sustainability is maintained, with ROE placed at the core of management indicators.
Dividend policy remains steady, with a focus on increasing total payout ratio above the 2026 Medium-Term Business Plan level.
Business portfolio transformation and growth strategy
Plans to expand in high-growth, high-profit domains by leveraging unique value propositions and open innovation.
Management resources will be allocated to confectionery and global strategic pharmaceutical products.
M&A and partnerships are actively pursued to accelerate commercialization and growth.
Withdrawal from non-strategic domains is underway to enhance overall profitability.
Targeting a 30% operating profit composition from overseas and new businesses by FY2035.
Latest events from Meiji
- Operating profit rose on Food segment strength, but net profit fell on higher costs and impairment.2269
Q3 202612 Feb 2026 - Pharmaceuticals drove profit growth as food margins fell; full-year outlook and share cancellation steady.2269
Q2 202515 Jan 2026 - Operating profit beat plan, but sales forecast lowered amid cost pressures and ongoing reforms.2269
Q2 202617 Nov 2025 - Profits declined in Q1, but full-year outlook and dividend plans remain strong.2269
Q1 20266 Aug 2025 - Sales and profit rose, led by pharmaceuticals, despite food margin pressures.2269
Q1 202513 Jun 2025 - Sales and profit growth continue, with higher dividends and strategic investments ahead.2269
Q4 20256 Jun 2025 - Sales growth offset by pharma and vaccine losses; outlook remains cautious.2269
Q3 20256 Jun 2025